Maplelane Capital’s MiMedx Group MDXG Stock Holding History

Maplelane Capital’s Portfolio MDXG Stock Details MDXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-300,000	Closed	-$1.92M	–	147
2018 Q2	$1.92M	Buy	+300,000	New	+$2.14M	0.04%	122
2017 Q3	–	Sell	-2,500	Closed	-$3.74M	–	159
2017 Q2	$3.74M	Sell	2,500 -247,500	-99%	-$3.3M	0.07%	111
2017 Q1	$2.38M	Buy	+250,000	New	+$2.11M	0.06%	105

Other funds holding MDXG

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

LCM

Lakewood Capital Management New York $1.58B AUM 0.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

Tiedemann Advisors New York $2.33B AUM 15.56% 1-Year Est. Return

Maplelane Capital's MDXG Position: Q3 2018 in Review

Maplelane Capital sold out of MiMedx Group (MDXG) in Q3 2018, closing a stake of 166,668 shares — an estimated $1.06M sold.

Maplelane Capital first reported a position in MDXG in Q1 2017 and held it in 3 quarters. The position peaked at $1.06M in Q2 2018. 186 funds tracked by Wall St. Rank hold MDXG as of Q3 2018.

Maplelane Capital reported no remaining MiMedx Group position as of Q3 2018 after selling out during the quarter.
Maplelane Capital sold 166,668 MiMedx Group shares in Q3 2018, an estimated $1.06M.
Maplelane Capital first reported a position in MiMedx Group in Q1 2017 and held it in 3 quarters.
Maplelane Capital's MiMedx Group position peaked at $1.06M in Q2 2018.
186 funds tracked by Wall St. Rank held MiMedx Group as of Q3 2018.

Based on Maplelane Capital's 13F filing for Q3 2018, filed 14 Nov 2018.